AVAX Technologies, Inc. (AVXT) to Present Results of Phase I-II Study of MVax(R) at 2008 Meeting of the American Society of Clinical Oncology  
3/24/2008 9:29:40 AM

PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTC Market:AVXT.OB) announces that its abstract, entitled, “Dose-response study of a cryopreserved, autologous, hapten-modified melanoma vaccine (MVax®),” has been accepted for presentation at the annual meeting of the American Society for Clinical Oncology (ASCO) to be held May 30-June 3 in Chicago. The abstract was selected from the over 4,800 that were reviewed by ASCO’s Scientific Program Committee this year.